
Roche cuts ties with Inovio in hepatitis B development
pharmafile | August 3, 2016 | News story | Research and Development | Inovio, Roche, hepatitis B
Inovio Pharmaceuticals has announced that it will independently continue development of hepatitis B immunotherapy, INO-1800, after Swiss drugmaker Roche issued notice that it would cease its licensing collaboration on the drug.
Roche only paid $10 million upfront to co-develop some of Inovio’s early stage pipeline assets, including, INO-1800 but the deal was worth a potential $422 million through milestone payments.
All rights granted to Roche related to INO-1800, including the right to license the product to other parties, will now be returned to Inovio. The company has signalled their intent to continue its current Phase I study of INO-1800, with enrolment anticipated in Q1 2017, and results expected in Q2 later that year.
CEO Dr Joseph Kim says: “While we acknowledge Roche’s strategic decision in the area of hepatitis B, we are optimistic that our potent immunotherapy platform will make a difference in this globally important chronic viral infection, similar to what we have demonstrated in HPV-related disease. Inovio was already managing the Phase I clinical trial so the study will continue on track without disruption.”
Investors didn’t share Kim’s optimism, with share sat Inovio falling 6% at the time of writing.
Sean Murray
Related Content

Global study calls for overhaul of hepatitis B care to meet WHO targets
A major global study has warned that current models of hepatitis B care are failing …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …






